Evelo Biosciences, Inc. (EVLO) News

Evelo Biosciences, Inc. (EVLO): $0.13

0.01 (+11.59%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add EVLO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#196 of 400

in industry

Filter EVLO News Items

EVLO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EVLO News Highlights

  • For EVLO, its 30 day story count is now at 3.
  • Over the past 7 days, the trend for EVLO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest EVLO News From Around the Web

Below are the latest news stories about EVELO BIOSCIENCES INC that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | May 17, 2023

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.

Yahoo | May 16, 2023

Evelo Biosciences Insiders Added US$575k Of Stock To Their Holdings \

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | May 10, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The biggest pre-market stock movers are a hot topic traders are going to want to know about with all the latest news on Friday!

William White on InvestorPlace | April 28, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

The biggest pre-market stock movers are ready to go as we dive into the latest news traders need to know about on Thursday!

William White on InvestorPlace | April 27, 2023

Why Is Atomera (ATOM) Stock Up 34% Today?

Atomera (ATOM) stock is taking off on Thursday following the release of its earnings report for the first quarter of 2023!

William White on InvestorPlace | April 27, 2023

Why Is Baudax Bio (BXRX) Stock Down 52% Today?

Baudax Bio (BXRX) stock is falling hard on Thursday after the pharmaceutical company announced a $4 million public stock offering.

William White on InvestorPlace | April 27, 2023

Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?

Evelo Biosciences (EVLO) stock is on the rise Thursday after the company said it's shifting focus toward EV development.

William White on InvestorPlace | April 27, 2023

Why Is Impinj (PI) Stock Down 25% Today?

Impinj (PI) stock is falling on Thursday after the radio-frequency chipmaker released its earnings report for the first quarter of 2023.

William White on InvestorPlace | April 27, 2023

Evelo Biosciences' Atopic Dermatitis Study Cohort Misses Primary Goal Again, Shuts Study, Lays Off More Staff

Evelo Biosciences Inc (NASDAQ: EVLO) said its fourth cohort of the EDP1815 Phase 2 trial in atopic dermatitis, consistent with the first three cohorts, failed to meet the primary endpoint of the proportion of patients who achieve an EASI-50 response at week 16. EASI-50 responses or greater were achieved at week 16 in 37.9% of patients dosed with EDP1815 versus 44.7% on placebo in the fourth cohort. Following the results, the company decided to cease further development of EDP1815 in atopic derma

Yahoo | April 26, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7667 seconds.